Russia’s Generium Announces First Biosimilar Of Soliris
Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.
You may also be interested in...
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.
Samsung Bioepis has seen its SB12 proposed eculizumab biosimilar rival to Soliris endorsed by the EMA’s CHMP. At the same time, three generics also received positive CHMP opinions.
Amgen has received a positive opinion from the EMA’s CHMP recommending that its Bekemv eculizumab biosimilar become the first Soliris rival to be granted a pan-European marketing authorization.